Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia.

British journal of haematology - 1 May 2004

Aplenc Richard, Lange Beverly

Abstract excerpt

Present day paediatric co-operative group acute lymphoblastic leukaemia (ALL) protocols cure approximately 80% of patients, a result achieved largely through the use of risk-stratified therapies that employ multiple chemotherapy agents. These risk-based therapies utilize host and leukaemia traits to select the most appropriate therapy. However, these risk-stratified approaches predict therapy response imperfectly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alkylating Agents
Share to Drug Resistance, Multiple
Share to Glucocorticoids

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunosuppressive Agents

Share to Mercaptopurine

Share to Methotrexate

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Share to Thioguanine

Source

Identifiers

PMID: 15142113
DOI: 10.1111/j.1365-2141.2004.04932.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia.PMID 15142113Read ↗

Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia.Semantic proximity Read ↗

Pharmacogenetics of Childhood Acute Lymphoblastic Leukemia.Semantic proximity Read ↗

Thiopurine S-methyltransferase pharmacogenetics in childhood acute lymphoblastic leukemia.Semantic proximity Read ↗

Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia.Semantic proximity Read ↗

Pharmacogenetics of Childhood Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

The Promise of Pharmacogenomics in Reducing Toxicity during Acute Lymphoblastic Leukemia Maintenance TreatmentSemantic proximity Read ↗

Pediatric Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in responses to chemotherapy.Semantic proximity Read ↗

Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemiaSemantic proximity Read ↗

Pharmacogenetic considerations for acute lymphoblastic leukemia therapies.Semantic proximity Read ↗

Implementation of Pharmacogenetics to Individualize Treatment Regimens for Children with Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Inherited genetic variation in childhood acute lymphoblastic leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.